recast-jats-buildd8e1462159jitcJ Immunother CancerjitcJournal for ImmunoTherapy of CancerJ Immunother CancerJ Immunother Cancer2051-1426BMJ Publishing Group Ltdjitc-2021-002644corr110.1136/jitc-2021-002644corr1/jitc/9/8/1.4.atomCorrectionOpen accessSpecial collectionsOpen accessCorrection: CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models8202113820211820211820219811© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.2021https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.special-featureunlocked

Puigdelloses M, Garcia-Moure M, Labiano S, et al. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models. Journal for ImmunoTherapy of Cancer 2021;9:e002644. doi: 10.1136/jitc-2021-002644

This paper has been updated since first published to amend author name 'Jaime Gállego Pérez-Larraya'.